Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
HIV-1 | 112 | 2024 | 6860 | 10.160 |
Why?
|
HIV Infections | 128 | 2024 | 17346 | 5.870 |
Why?
|
CD4-Positive T-Lymphocytes | 56 | 2024 | 4371 | 5.360 |
Why?
|
Proviruses | 23 | 2024 | 313 | 5.290 |
Why?
|
Virus Latency | 20 | 2024 | 363 | 5.060 |
Why?
|
HIV Seropositivity | 9 | 2023 | 960 | 2.450 |
Why?
|
CD8-Positive T-Lymphocytes | 42 | 2022 | 4576 | 2.270 |
Why?
|
HIV Long-Term Survivors | 9 | 2018 | 121 | 2.200 |
Why?
|
Viral Load | 39 | 2024 | 3330 | 2.190 |
Why?
|
Anti-Retroviral Agents | 19 | 2024 | 1782 | 1.930 |
Why?
|
DNA, Viral | 16 | 2022 | 2201 | 1.920 |
Why?
|
Disease Reservoirs | 8 | 2020 | 121 | 1.570 |
Why?
|
T-Lymphocyte Subsets | 8 | 2022 | 1805 | 1.270 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p21 | 3 | 2014 | 359 | 1.130 |
Why?
|
T-Lymphocytes, Helper-Inducer | 5 | 2020 | 973 | 1.090 |
Why?
|
Histone Deacetylase Inhibitors | 3 | 2024 | 774 | 1.060 |
Why?
|
Virus Replication | 17 | 2024 | 2435 | 1.060 |
Why?
|
Anti-HIV Agents | 20 | 2024 | 4524 | 1.030 |
Why?
|
Genome, Viral | 4 | 2020 | 665 | 1.000 |
Why?
|
Viremia | 15 | 2024 | 707 | 0.990 |
Why?
|
Virus Integration | 5 | 2024 | 304 | 0.960 |
Why?
|
Receptors, HIV | 2 | 2017 | 159 | 0.940 |
Why?
|
Interferon-alpha | 5 | 2024 | 921 | 0.930 |
Why?
|
Immunity, Innate | 9 | 2024 | 3060 | 0.850 |
Why?
|
Antiretroviral Therapy, Highly Active | 16 | 2019 | 1896 | 0.830 |
Why?
|
Dendritic Cells | 18 | 2023 | 2746 | 0.790 |
Why?
|
Th1 Cells | 3 | 2020 | 1037 | 0.780 |
Why?
|
T-Lymphocytes, Cytotoxic | 15 | 2022 | 1783 | 0.730 |
Why?
|
Viral Tropism | 2 | 2017 | 102 | 0.680 |
Why?
|
Immunologic Memory | 5 | 2023 | 1359 | 0.650 |
Why?
|
AIDS Vaccines | 8 | 2024 | 896 | 0.620 |
Why?
|
Phylogeny | 5 | 2022 | 2809 | 0.610 |
Why?
|
Acquired Immunodeficiency Syndrome | 9 | 2009 | 2199 | 0.590 |
Why?
|
Histocompatibility Antigens Class I | 10 | 2022 | 1355 | 0.550 |
Why?
|
Killer Cells, Natural | 10 | 2023 | 2203 | 0.540 |
Why?
|
Hydroxamic Acids | 3 | 2016 | 481 | 0.530 |
Why?
|
Hepatitis C | 4 | 2018 | 1584 | 0.530 |
Why?
|
HIV | 6 | 2021 | 1582 | 0.530 |
Why?
|
Humans | 156 | 2024 | 761326 | 0.510 |
Why?
|
Base Sequence | 8 | 2022 | 12449 | 0.500 |
Why?
|
Evolution, Molecular | 5 | 2019 | 1888 | 0.500 |
Why?
|
Cyclin-Dependent Kinase 2 | 2 | 2014 | 184 | 0.480 |
Why?
|
HIV Antibodies | 5 | 2023 | 1303 | 0.470 |
Why?
|
Ribavirin | 3 | 2018 | 395 | 0.470 |
Why?
|
Receptors, Immunologic | 6 | 2014 | 1412 | 0.460 |
Why?
|
Telomerase | 2 | 2010 | 745 | 0.460 |
Why?
|
Leukocytes, Mononuclear | 9 | 2024 | 1842 | 0.460 |
Why?
|
Lymphoid Progenitor Cells | 1 | 2014 | 20 | 0.460 |
Why?
|
Lymph Nodes | 4 | 2023 | 3469 | 0.440 |
Why?
|
HIV Reverse Transcriptase | 1 | 2014 | 212 | 0.440 |
Why?
|
RNA, Viral | 11 | 2024 | 2846 | 0.430 |
Why?
|
CD4 Lymphocyte Count | 11 | 2024 | 2569 | 0.420 |
Why?
|
Receptors, CXCR4 | 1 | 2017 | 727 | 0.420 |
Why?
|
Cell Polarity | 1 | 2015 | 637 | 0.400 |
Why?
|
Monocytes | 5 | 2020 | 2573 | 0.400 |
Why?
|
Simian Acquired Immunodeficiency Syndrome | 3 | 2023 | 541 | 0.390 |
Why?
|
Epitopes, T-Lymphocyte | 11 | 2021 | 825 | 0.390 |
Why?
|
Receptors, CCR5 | 3 | 2021 | 486 | 0.390 |
Why?
|
Telomere-Binding Proteins | 1 | 2012 | 119 | 0.380 |
Why?
|
Hematologic Neoplasms | 1 | 2023 | 1896 | 0.370 |
Why?
|
Myeloid Cells | 3 | 2021 | 823 | 0.370 |
Why?
|
Antigen Presentation | 7 | 2012 | 1254 | 0.370 |
Why?
|
Indoles | 3 | 2016 | 1832 | 0.370 |
Why?
|
Botswana | 6 | 2023 | 1048 | 0.360 |
Why?
|
HLA-B Antigens | 5 | 2016 | 331 | 0.360 |
Why?
|
Ritonavir | 2 | 2003 | 329 | 0.360 |
Why?
|
Reverse Transcriptase Inhibitors | 3 | 2020 | 621 | 0.340 |
Why?
|
HIV Protease Inhibitors | 2 | 2003 | 432 | 0.340 |
Why?
|
Daptomycin | 1 | 2009 | 71 | 0.330 |
Why?
|
Heterochromatin | 2 | 2023 | 293 | 0.320 |
Why?
|
Stem Cells | 4 | 2019 | 3521 | 0.320 |
Why?
|
Flow Cytometry | 11 | 2017 | 5866 | 0.320 |
Why?
|
Th17 Cells | 1 | 2015 | 793 | 0.320 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2012 | 696 | 0.320 |
Why?
|
Antiviral Agents | 6 | 2023 | 3057 | 0.320 |
Why?
|
Transcription, Genetic | 2 | 2022 | 7597 | 0.310 |
Why?
|
HIV Envelope Protein gp120 | 2 | 2014 | 914 | 0.310 |
Why?
|
Glycopeptides | 1 | 2009 | 220 | 0.310 |
Why?
|
Infectious Disease Transmission, Vertical | 4 | 2024 | 1351 | 0.300 |
Why?
|
HLA-A3 Antigen | 2 | 2006 | 34 | 0.290 |
Why?
|
Phenotype | 2 | 2023 | 16603 | 0.290 |
Why?
|
Chromosomes, Human | 2 | 2019 | 442 | 0.280 |
Why?
|
Toll-Like Receptor 9 | 2 | 2019 | 233 | 0.280 |
Why?
|
Simian immunodeficiency virus | 3 | 2023 | 809 | 0.280 |
Why?
|
Virus Activation | 3 | 2020 | 322 | 0.270 |
Why?
|
Genes, T-Cell Receptor beta | 1 | 2006 | 71 | 0.270 |
Why?
|
Antibodies, Neutralizing | 3 | 2023 | 1943 | 0.270 |
Why?
|
Adult | 54 | 2024 | 221122 | 0.260 |
Why?
|
Endocarditis, Bacterial | 1 | 2009 | 444 | 0.250 |
Why?
|
Middle Aged | 47 | 2024 | 220774 | 0.250 |
Why?
|
Cell Survival | 6 | 2023 | 5792 | 0.240 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2023 | 5670 | 0.240 |
Why?
|
Cell Proliferation | 8 | 2024 | 10431 | 0.240 |
Why?
|
Genes, nef | 1 | 2004 | 52 | 0.240 |
Why?
|
Down-Regulation | 1 | 2012 | 2913 | 0.240 |
Why?
|
Hemophilia B | 1 | 2005 | 84 | 0.240 |
Why?
|
Cytotoxicity, Immunologic | 3 | 2014 | 1351 | 0.230 |
Why?
|
Female | 60 | 2024 | 392485 | 0.230 |
Why?
|
Male | 57 | 2024 | 360621 | 0.230 |
Why?
|
Immunity, Cellular | 5 | 2015 | 1560 | 0.230 |
Why?
|
Receptors, Antigen, T-Cell, alpha-beta | 3 | 2022 | 800 | 0.220 |
Why?
|
Leukocytes | 1 | 2011 | 2029 | 0.220 |
Why?
|
Receptors, Chemokine | 2 | 2007 | 653 | 0.220 |
Why?
|
Interferon-gamma | 7 | 2015 | 3159 | 0.220 |
Why?
|
High-Throughput Nucleotide Sequencing | 4 | 2021 | 3638 | 0.220 |
Why?
|
Receptors, Interleukin-21 | 1 | 2023 | 32 | 0.220 |
Why?
|
Mozambique | 1 | 2022 | 55 | 0.210 |
Why?
|
Interleukins | 3 | 2017 | 782 | 0.210 |
Why?
|
Liver Failure | 1 | 2005 | 250 | 0.210 |
Why?
|
Infant, Newborn | 8 | 2024 | 26211 | 0.210 |
Why?
|
Alleles | 7 | 2022 | 6909 | 0.210 |
Why?
|
Membrane Glycoproteins | 6 | 2014 | 3701 | 0.210 |
Why?
|
nef Gene Products, Human Immunodeficiency Virus | 4 | 2014 | 148 | 0.200 |
Why?
|
Ionomycin | 1 | 2022 | 110 | 0.200 |
Why?
|
Sequence Analysis, DNA | 3 | 2022 | 4740 | 0.200 |
Why?
|
Drug Resistance, Bacterial | 1 | 2009 | 1058 | 0.200 |
Why?
|
Indinavir | 1 | 2002 | 73 | 0.200 |
Why?
|
Sarcoma, Kaposi | 1 | 2005 | 374 | 0.200 |
Why?
|
B-Lymphocyte Subsets | 1 | 2023 | 239 | 0.200 |
Why?
|
Gene Products, gag | 4 | 2007 | 312 | 0.200 |
Why?
|
Delusions | 1 | 2024 | 298 | 0.190 |
Why?
|
Hemophilia A | 1 | 2005 | 360 | 0.190 |
Why?
|
Molecular Sequence Data | 13 | 2014 | 17640 | 0.190 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2005 | 678 | 0.190 |
Why?
|
Cyclin-Dependent Kinase 9 | 2 | 2011 | 67 | 0.190 |
Why?
|
Antigens, CD | 6 | 2015 | 4000 | 0.190 |
Why?
|
Tetradecanoylphorbol Acetate | 1 | 2022 | 818 | 0.180 |
Why?
|
Species Specificity | 4 | 2014 | 2419 | 0.180 |
Why?
|
Basal Ganglia | 1 | 2023 | 554 | 0.180 |
Why?
|
Heterocyclic Compounds, 3-Ring | 2 | 2020 | 285 | 0.180 |
Why?
|
Genes, MHC Class I | 4 | 2010 | 240 | 0.180 |
Why?
|
Staphylococcal Infections | 1 | 2009 | 1409 | 0.180 |
Why?
|
Lymphocyte Activation | 5 | 2020 | 5491 | 0.180 |
Why?
|
Receptors, Lymphocyte Homing | 1 | 2000 | 141 | 0.170 |
Why?
|
Up-Regulation | 4 | 2014 | 4120 | 0.170 |
Why?
|
HLA Antigens | 3 | 2011 | 1371 | 0.170 |
Why?
|
Integrins | 2 | 2024 | 834 | 0.170 |
Why?
|
Lectins, C-Type | 1 | 2003 | 584 | 0.170 |
Why?
|
Gene Expression Profiling | 5 | 2020 | 9414 | 0.170 |
Why?
|
Acute Disease | 7 | 2019 | 7238 | 0.160 |
Why?
|
Cells, Cultured | 8 | 2020 | 18962 | 0.160 |
Why?
|
Hematopoietic Stem Cell Mobilization | 1 | 2000 | 225 | 0.160 |
Why?
|
Lymphocyte Subsets | 2 | 2014 | 311 | 0.160 |
Why?
|
Amino Acid Sequence | 13 | 2014 | 13446 | 0.160 |
Why?
|
Antiphospholipid Syndrome | 1 | 2020 | 165 | 0.160 |
Why?
|
Pyrimidinones | 2 | 2019 | 385 | 0.150 |
Why?
|
Doxorubicin | 1 | 2005 | 2215 | 0.150 |
Why?
|
Helicobacter pylori | 1 | 2002 | 377 | 0.150 |
Why?
|
Helicobacter Infections | 1 | 2002 | 386 | 0.150 |
Why?
|
Clone Cells | 1 | 2022 | 1661 | 0.150 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 2002 | 662 | 0.150 |
Why?
|
South Africa | 2 | 2024 | 1841 | 0.150 |
Why?
|
Antigens, CD34 | 1 | 2000 | 658 | 0.150 |
Why?
|
Germinal Center | 1 | 2020 | 380 | 0.150 |
Why?
|
Hepatitis C, Chronic | 2 | 2002 | 1032 | 0.140 |
Why?
|
Tumor Necrosis Factor-alpha | 4 | 2020 | 4355 | 0.140 |
Why?
|
DNA Mutational Analysis | 2 | 2019 | 4108 | 0.140 |
Why?
|
Cell Adhesion Molecules | 1 | 2003 | 1600 | 0.140 |
Why?
|
Interferons | 2 | 2022 | 705 | 0.140 |
Why?
|
Fatty Liver | 1 | 2003 | 788 | 0.140 |
Why?
|
Biological Evolution | 1 | 2022 | 1073 | 0.130 |
Why?
|
Gene Silencing | 2 | 2020 | 1509 | 0.130 |
Why?
|
Infant | 8 | 2024 | 36202 | 0.130 |
Why?
|
Gene Products, nef | 2 | 2006 | 100 | 0.130 |
Why?
|
Immunocompromised Host | 1 | 2020 | 856 | 0.120 |
Why?
|
Vaccines, Subunit | 2 | 2014 | 161 | 0.120 |
Why?
|
Aged | 16 | 2022 | 169179 | 0.120 |
Why?
|
Drug Administration Schedule | 4 | 2018 | 4850 | 0.120 |
Why?
|
Young Adult | 11 | 2020 | 59196 | 0.120 |
Why?
|
Reverse Transcription | 1 | 2014 | 47 | 0.120 |
Why?
|
DNA | 2 | 2019 | 7216 | 0.120 |
Why?
|
T-Lymphocytes | 3 | 2017 | 10191 | 0.120 |
Why?
|
Caspase 8 | 1 | 2014 | 189 | 0.120 |
Why?
|
HIV Antigens | 2 | 2005 | 325 | 0.120 |
Why?
|
Metabolic Networks and Pathways | 1 | 2018 | 787 | 0.110 |
Why?
|
Cohort Studies | 14 | 2018 | 41440 | 0.110 |
Why?
|
Immunodominant Epitopes | 5 | 2006 | 240 | 0.110 |
Why?
|
Enzyme Stability | 1 | 2014 | 219 | 0.110 |
Why?
|
Cell Count | 2 | 2015 | 1835 | 0.110 |
Why?
|
Depsipeptides | 1 | 2014 | 95 | 0.110 |
Why?
|
Host-Pathogen Interactions | 3 | 2021 | 1457 | 0.110 |
Why?
|
Toll-Like Receptor 1 | 1 | 2013 | 47 | 0.110 |
Why?
|
Receptors, Antigen, T-Cell | 3 | 2007 | 2549 | 0.110 |
Why?
|
Phosphopeptides | 1 | 2014 | 240 | 0.110 |
Why?
|
Receptors, Cell Surface | 1 | 2003 | 2820 | 0.110 |
Why?
|
Lipopeptides | 1 | 2013 | 71 | 0.110 |
Why?
|
Case-Control Studies | 6 | 2024 | 22124 | 0.110 |
Why?
|
Disease Progression | 8 | 2017 | 13500 | 0.110 |
Why?
|
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2014 | 507 | 0.110 |
Why?
|
Polyethylene Glycols | 1 | 2018 | 1188 | 0.100 |
Why?
|
HLA-DR Antigens | 2 | 2012 | 631 | 0.100 |
Why?
|
Liver | 2 | 2005 | 7531 | 0.100 |
Why?
|
Polymerase Chain Reaction | 6 | 2020 | 6086 | 0.100 |
Why?
|
Rectum | 1 | 2017 | 892 | 0.100 |
Why?
|
Genotype | 4 | 2021 | 12982 | 0.100 |
Why?
|
tat Gene Products, Human Immunodeficiency Virus | 1 | 2012 | 119 | 0.100 |
Why?
|
Time Factors | 6 | 2019 | 39974 | 0.100 |
Why?
|
Toll-Like Receptor 2 | 1 | 2013 | 345 | 0.100 |
Why?
|
Drug Therapy, Combination | 5 | 2006 | 6309 | 0.100 |
Why?
|
Epigenesis, Genetic | 2 | 2022 | 3793 | 0.090 |
Why?
|
RNA, Small Interfering | 4 | 2015 | 3428 | 0.090 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2014 | 1540 | 0.090 |
Why?
|
Anti-Bacterial Agents | 1 | 2009 | 7439 | 0.090 |
Why?
|
Nevirapine | 2 | 2023 | 273 | 0.090 |
Why?
|
env Gene Products, Human Immunodeficiency Virus | 1 | 2014 | 369 | 0.090 |
Why?
|
Histone Deacetylases | 1 | 2015 | 719 | 0.090 |
Why?
|
Prospective Studies | 5 | 2024 | 54405 | 0.090 |
Why?
|
DNA Primers | 3 | 2011 | 2820 | 0.090 |
Why?
|
RNA, Messenger | 4 | 2011 | 12787 | 0.090 |
Why?
|
Genetic Variation | 4 | 2019 | 6571 | 0.090 |
Why?
|
Receptors, CXCR5 | 2 | 2023 | 87 | 0.090 |
Why?
|
Th2 Cells | 1 | 2015 | 1058 | 0.090 |
Why?
|
Immunologic Factors | 1 | 2019 | 1589 | 0.090 |
Why?
|
Chromatin | 1 | 2022 | 2960 | 0.090 |
Why?
|
Sequence Analysis, RNA | 1 | 2018 | 2019 | 0.090 |
Why?
|
Cytokines | 5 | 2017 | 7390 | 0.080 |
Why?
|
HLA-A Antigens | 2 | 2006 | 226 | 0.080 |
Why?
|
Immunophenotyping | 3 | 2014 | 1870 | 0.080 |
Why?
|
Early Diagnosis | 1 | 2013 | 1184 | 0.080 |
Why?
|
Statistics, Nonparametric | 1 | 2014 | 2853 | 0.080 |
Why?
|
Child | 7 | 2024 | 80156 | 0.080 |
Why?
|
Apoptosis | 2 | 2018 | 9474 | 0.070 |
Why?
|
HLA-B27 Antigen | 1 | 2007 | 63 | 0.070 |
Why?
|
Disease Transmission, Infectious | 1 | 2013 | 559 | 0.070 |
Why?
|
Oxazines | 2 | 2020 | 349 | 0.070 |
Why?
|
Hematopoietic Stem Cells | 1 | 2000 | 3396 | 0.070 |
Why?
|
Inflammation | 2 | 2024 | 10760 | 0.070 |
Why?
|
RNA Polymerase II | 1 | 2011 | 539 | 0.070 |
Why?
|
International Cooperation | 1 | 2014 | 1428 | 0.070 |
Why?
|
Withholding Treatment | 2 | 2024 | 617 | 0.070 |
Why?
|
Mutation | 7 | 2021 | 30044 | 0.070 |
Why?
|
Cluster Analysis | 1 | 2014 | 2712 | 0.070 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 4567 | 0.070 |
Why?
|
Phosphorylation | 2 | 2014 | 8312 | 0.070 |
Why?
|
Drug Resistance, Viral | 2 | 2021 | 861 | 0.070 |
Why?
|
Adjuvants, Immunologic | 1 | 2012 | 1036 | 0.070 |
Why?
|
Cell Degranulation | 1 | 2007 | 276 | 0.070 |
Why?
|
B-Lymphocytes | 4 | 2020 | 4764 | 0.060 |
Why?
|
Intestinal Mucosa | 1 | 2017 | 3027 | 0.060 |
Why?
|
Diseases in Twins | 1 | 2007 | 447 | 0.060 |
Why?
|
Longitudinal Studies | 3 | 2019 | 14597 | 0.060 |
Why?
|
MicroRNAs | 1 | 2021 | 3796 | 0.060 |
Why?
|
Viral Regulatory and Accessory Proteins | 1 | 2005 | 153 | 0.060 |
Why?
|
HLA-A2 Antigen | 1 | 2005 | 211 | 0.060 |
Why?
|
Child, Preschool | 6 | 2024 | 42251 | 0.060 |
Why?
|
Pyridones | 2 | 2020 | 808 | 0.060 |
Why?
|
Viral Structural Proteins | 1 | 2004 | 95 | 0.060 |
Why?
|
Ligands | 2 | 2008 | 3271 | 0.060 |
Why?
|
Chemotaxis, Leukocyte | 1 | 2007 | 664 | 0.060 |
Why?
|
Gene Expression Regulation | 4 | 2020 | 11900 | 0.060 |
Why?
|
Cross Reactions | 1 | 2006 | 818 | 0.060 |
Why?
|
Lamivudine | 2 | 2021 | 365 | 0.060 |
Why?
|
Signal Transduction | 4 | 2021 | 23427 | 0.060 |
Why?
|
Interleukin-12 | 2 | 2020 | 583 | 0.060 |
Why?
|
Immunoglobulin D | 1 | 2023 | 57 | 0.060 |
Why?
|
Amino Acid Substitution | 2 | 2006 | 1737 | 0.050 |
Why?
|
Zidovudine | 2 | 2021 | 624 | 0.050 |
Why?
|
RNA | 2 | 2023 | 2723 | 0.050 |
Why?
|
Interleukin-2 | 2 | 2014 | 1891 | 0.050 |
Why?
|
Genes, Viral | 1 | 2004 | 649 | 0.050 |
Why?
|
HIV-2 | 1 | 2023 | 156 | 0.050 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2008 | 1135 | 0.050 |
Why?
|
Hepatomegaly | 1 | 2003 | 84 | 0.050 |
Why?
|
Interleukin-15 | 1 | 2023 | 185 | 0.050 |
Why?
|
RNA Interference | 1 | 2011 | 2832 | 0.050 |
Why?
|
Immune Tolerance | 1 | 2012 | 2300 | 0.050 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2012 | 2423 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3080 | 0.050 |
Why?
|
Receptors, CCR1 | 1 | 2002 | 31 | 0.050 |
Why?
|
Lung Diseases, Fungal | 1 | 2003 | 126 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3200 | 0.050 |
Why?
|
Gene Expression | 1 | 2015 | 7582 | 0.050 |
Why?
|
Chemokine CCL3 | 1 | 2002 | 84 | 0.050 |
Why?
|
CD4-CD8 Ratio | 1 | 2002 | 114 | 0.050 |
Why?
|
Chemokine CCL4 | 1 | 2002 | 126 | 0.050 |
Why?
|
Macrophage Inflammatory Proteins | 1 | 2002 | 121 | 0.050 |
Why?
|
Receptors, CCR4 | 1 | 2002 | 77 | 0.050 |
Why?
|
Tandem Repeat Sequences | 1 | 2003 | 180 | 0.050 |
Why?
|
Mitochondria, Liver | 1 | 2003 | 190 | 0.050 |
Why?
|
Transaminases | 1 | 2003 | 198 | 0.050 |
Why?
|
Telomere | 1 | 2008 | 941 | 0.050 |
Why?
|
gag Gene Products, Human Immunodeficiency Virus | 2 | 2018 | 206 | 0.050 |
Why?
|
Ileum | 1 | 2024 | 557 | 0.050 |
Why?
|
Receptors, CXCR3 | 2 | 2017 | 238 | 0.050 |
Why?
|
Macaca mulatta | 2 | 2019 | 2332 | 0.050 |
Why?
|
Caspase 3 | 1 | 2004 | 729 | 0.050 |
Why?
|
Cross-Sectional Studies | 5 | 2017 | 26108 | 0.050 |
Why?
|
Chemokine CCL5 | 1 | 2002 | 215 | 0.050 |
Why?
|
Evidence-Based Medicine | 1 | 2013 | 3687 | 0.050 |
Why?
|
Liposomes | 1 | 2005 | 783 | 0.050 |
Why?
|
Proteins | 1 | 2016 | 6034 | 0.050 |
Why?
|
Argentina | 1 | 2021 | 247 | 0.050 |
Why?
|
Caspases | 1 | 2004 | 877 | 0.050 |
Why?
|
Boston | 1 | 2014 | 9333 | 0.050 |
Why?
|
HIV Core Protein p24 | 2 | 2014 | 245 | 0.050 |
Why?
|
Animals | 7 | 2023 | 168388 | 0.050 |
Why?
|
Nucleotidyltransferases | 1 | 2022 | 243 | 0.040 |
Why?
|
DNA, Satellite | 1 | 2020 | 67 | 0.040 |
Why?
|
Linear Models | 3 | 2016 | 5871 | 0.040 |
Why?
|
Epitopes | 4 | 2010 | 2504 | 0.040 |
Why?
|
Integrin alpha4beta1 | 1 | 2000 | 119 | 0.040 |
Why?
|
STAT4 Transcription Factor | 1 | 2020 | 93 | 0.040 |
Why?
|
Transcription Initiation Site | 1 | 2020 | 188 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-bcl-6 | 1 | 2020 | 191 | 0.040 |
Why?
|
Mycoses | 1 | 2003 | 386 | 0.040 |
Why?
|
Substrate Specificity | 1 | 2004 | 1793 | 0.040 |
Why?
|
Culicidae | 1 | 2020 | 108 | 0.040 |
Why?
|
Drug Design | 1 | 2005 | 1050 | 0.040 |
Why?
|
Nausea | 1 | 2003 | 679 | 0.040 |
Why?
|
Pregnancy | 4 | 2024 | 29858 | 0.040 |
Why?
|
Centromere | 1 | 2020 | 213 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 2 | 2016 | 17872 | 0.040 |
Why?
|
CREB-Binding Protein | 1 | 2019 | 148 | 0.040 |
Why?
|
Recombinant Proteins | 2 | 2018 | 6525 | 0.040 |
Why?
|
Germany | 1 | 2002 | 875 | 0.040 |
Why?
|
Vomiting | 1 | 2003 | 652 | 0.040 |
Why?
|
Piperazines | 2 | 2020 | 2519 | 0.040 |
Why?
|
Chromosomes, Human, Pair 19 | 1 | 2020 | 349 | 0.040 |
Why?
|
Alkynes | 1 | 2020 | 320 | 0.040 |
Why?
|
Remission Induction | 1 | 2005 | 2395 | 0.040 |
Why?
|
Surface Properties | 1 | 2002 | 1160 | 0.040 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2013 | 3075 | 0.040 |
Why?
|
Follow-Up Studies | 2 | 2019 | 39108 | 0.040 |
Why?
|
Oxidative Phosphorylation | 1 | 2021 | 497 | 0.040 |
Why?
|
AIDS Serodiagnosis | 1 | 2020 | 220 | 0.040 |
Why?
|
Treatment Outcome | 6 | 2019 | 64645 | 0.040 |
Why?
|
Cyclopropanes | 1 | 2020 | 432 | 0.040 |
Why?
|
Defective Viruses | 1 | 2018 | 89 | 0.040 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 3 | 2016 | 3806 | 0.040 |
Why?
|
Benzoxazines | 1 | 2020 | 316 | 0.040 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 1 | 2000 | 691 | 0.040 |
Why?
|
Algorithms | 2 | 2020 | 14025 | 0.040 |
Why?
|
Endothelium | 1 | 2000 | 765 | 0.040 |
Why?
|
Glycosylation | 1 | 2020 | 1098 | 0.040 |
Why?
|
2',5'-Oligoadenylate Synthetase | 1 | 2017 | 27 | 0.040 |
Why?
|
Double-Blind Method | 1 | 2012 | 12329 | 0.040 |
Why?
|
Lactic Acid | 1 | 2003 | 1137 | 0.040 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2000 | 629 | 0.040 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2024 | 10203 | 0.040 |
Why?
|
Cercocebus atys | 1 | 2017 | 12 | 0.040 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2016 | 15879 | 0.040 |
Why?
|
Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2017 | 117 | 0.040 |
Why?
|
Viral Proteins | 1 | 2004 | 1803 | 0.030 |
Why?
|
Glycolysis | 1 | 2021 | 836 | 0.030 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily B | 1 | 2017 | 84 | 0.030 |
Why?
|
Spain | 1 | 2018 | 489 | 0.030 |
Why?
|
Peptides | 2 | 2010 | 4342 | 0.030 |
Why?
|
Magnesium | 1 | 2000 | 809 | 0.030 |
Why?
|
Leukemia, T-Cell | 1 | 2017 | 101 | 0.030 |
Why?
|
Brain | 1 | 2023 | 27103 | 0.030 |
Why?
|
Receptors, CCR6 | 1 | 2017 | 73 | 0.030 |
Why?
|
Coculture Techniques | 1 | 2000 | 1341 | 0.030 |
Why?
|
Abdominal Pain | 1 | 2003 | 1071 | 0.030 |
Why?
|
Blotting, Western | 2 | 2015 | 5034 | 0.030 |
Why?
|
Retrospective Studies | 5 | 2013 | 80575 | 0.030 |
Why?
|
Fibrosis | 1 | 2023 | 2048 | 0.030 |
Why?
|
Enzyme-Linked Immunospot Assay | 1 | 2016 | 123 | 0.030 |
Why?
|
Fatal Outcome | 1 | 2020 | 1833 | 0.030 |
Why?
|
Microarray Analysis | 1 | 2018 | 748 | 0.030 |
Why?
|
Ubiquitins | 1 | 2017 | 366 | 0.030 |
Why?
|
Neonatal Screening | 1 | 2020 | 597 | 0.030 |
Why?
|
Cyclin A | 1 | 2014 | 60 | 0.030 |
Why?
|
Lymphocyte Culture Test, Mixed | 1 | 2015 | 516 | 0.030 |
Why?
|
Outpatients | 1 | 2003 | 1596 | 0.030 |
Why?
|
Cell Line | 2 | 2020 | 15599 | 0.030 |
Why?
|
Interleukin-6 | 1 | 2024 | 3210 | 0.030 |
Why?
|
beta Catenin | 1 | 2019 | 1040 | 0.030 |
Why?
|
Diagnostic Tests, Routine | 1 | 2020 | 787 | 0.030 |
Why?
|
Adoptive Transfer | 1 | 2017 | 819 | 0.030 |
Why?
|
Spleen | 1 | 2020 | 2296 | 0.030 |
Why?
|
Gene Products, tat | 1 | 2014 | 111 | 0.030 |
Why?
|
Drug Combinations | 1 | 2020 | 2048 | 0.030 |
Why?
|
Epitope Mapping | 2 | 2005 | 297 | 0.030 |
Why?
|
Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2014 | 140 | 0.030 |
Why?
|
Cell Adhesion | 1 | 2000 | 3089 | 0.030 |
Why?
|
Chronic Disease | 2 | 2005 | 9319 | 0.030 |
Why?
|
Adolescent | 3 | 2013 | 88305 | 0.030 |
Why?
|
Bystander Effect | 1 | 2013 | 90 | 0.030 |
Why?
|
Staining and Labeling | 1 | 2017 | 1085 | 0.030 |
Why?
|
Polymorphism, Genetic | 1 | 2003 | 4286 | 0.030 |
Why?
|
Medication Adherence | 1 | 2024 | 2176 | 0.030 |
Why?
|
Calibration | 1 | 2014 | 818 | 0.030 |
Why?
|
Vaccines, Synthetic | 1 | 2014 | 619 | 0.020 |
Why?
|
Hepacivirus | 1 | 2018 | 1337 | 0.020 |
Why?
|
Proteomics | 1 | 2024 | 3843 | 0.020 |
Why?
|
Survival Rate | 1 | 2005 | 12710 | 0.020 |
Why?
|
Biopsy | 1 | 2003 | 6768 | 0.020 |
Why?
|
Pregnancy Outcome | 1 | 2021 | 2920 | 0.020 |
Why?
|
Cell Differentiation | 2 | 2019 | 11531 | 0.020 |
Why?
|
Gene Knockdown Techniques | 1 | 2015 | 1611 | 0.020 |
Why?
|
Necrosis | 1 | 2014 | 1605 | 0.020 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2017 | 1624 | 0.020 |
Why?
|
Mothers | 1 | 2020 | 2192 | 0.020 |
Why?
|
Repressor Proteins | 1 | 2020 | 2985 | 0.020 |
Why?
|
Stem Cell Transplantation | 1 | 2017 | 1598 | 0.020 |
Why?
|
Recurrence | 1 | 2021 | 8470 | 0.020 |
Why?
|
Enzyme Activation | 1 | 2014 | 3592 | 0.020 |
Why?
|
Massachusetts | 1 | 2021 | 8837 | 0.020 |
Why?
|
Solubility | 1 | 2010 | 1091 | 0.020 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2017 | 1549 | 0.020 |
Why?
|
Reproducibility of Results | 2 | 2018 | 20092 | 0.020 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2020 | 2152 | 0.020 |
Why?
|
Protein Binding | 1 | 2000 | 9351 | 0.020 |
Why?
|
Recombinant Fusion Proteins | 1 | 2016 | 3734 | 0.020 |
Why?
|
Comorbidity | 1 | 2002 | 10498 | 0.020 |
Why?
|
Severity of Illness Index | 1 | 2005 | 15835 | 0.020 |
Why?
|
Stavudine | 1 | 2006 | 85 | 0.020 |
Why?
|
Single-Cell Analysis | 1 | 2018 | 2448 | 0.020 |
Why?
|
Antigenic Variation | 1 | 2006 | 118 | 0.020 |
Why?
|
Kinetics | 1 | 2014 | 6374 | 0.020 |
Why?
|
Disease Susceptibility | 1 | 2013 | 1791 | 0.020 |
Why?
|
Twins, Monozygotic | 1 | 2007 | 470 | 0.020 |
Why?
|
Homeostasis | 1 | 2017 | 3322 | 0.020 |
Why?
|
Gene Products, vpr | 1 | 2005 | 33 | 0.020 |
Why?
|
vpr Gene Products, Human Immunodeficiency Virus | 1 | 2005 | 36 | 0.020 |
Why?
|
Risk Factors | 2 | 2024 | 74152 | 0.020 |
Why?
|
Proto-Oncogene Proteins | 1 | 2017 | 4509 | 0.020 |
Why?
|
Lysosomal-Associated Membrane Protein 1 | 1 | 2004 | 25 | 0.020 |
Why?
|
Consensus Sequence | 1 | 2005 | 365 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2020 | 14665 | 0.020 |
Why?
|
Cell Movement | 1 | 2017 | 5202 | 0.010 |
Why?
|
Histocompatibility Testing | 1 | 2006 | 719 | 0.010 |
Why?
|
Aged, 80 and over | 2 | 2020 | 58946 | 0.010 |
Why?
|
Mass Screening | 1 | 2020 | 5428 | 0.010 |
Why?
|
Autoimmune Diseases | 1 | 2017 | 2248 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2020 | 7999 | 0.010 |
Why?
|
Aspergillus niger | 1 | 2003 | 18 | 0.010 |
Why?
|
Aspergillus flavus | 1 | 2003 | 14 | 0.010 |
Why?
|
Scedosporium | 1 | 2003 | 10 | 0.010 |
Why?
|
Lung | 1 | 2022 | 9994 | 0.010 |
Why?
|
Fusarium | 1 | 2003 | 51 | 0.010 |
Why?
|
Aspergillus | 1 | 2003 | 93 | 0.010 |
Why?
|
Lymphocyte Count | 1 | 2005 | 778 | 0.010 |
Why?
|
Thermodynamics | 1 | 2004 | 595 | 0.010 |
Why?
|
Peptide Fragments | 1 | 2014 | 5114 | 0.010 |
Why?
|
Genomics | 1 | 2018 | 5817 | 0.010 |
Why?
|
Aspergillus fumigatus | 1 | 2003 | 157 | 0.010 |
Why?
|
Vaccination | 1 | 2014 | 3381 | 0.010 |
Why?
|
Conserved Sequence | 1 | 2005 | 1164 | 0.010 |
Why?
|
Aspergillosis | 1 | 2003 | 243 | 0.010 |
Why?
|
Bronchoalveolar Lavage Fluid | 1 | 2003 | 754 | 0.010 |
Why?
|
Pandemics | 1 | 2020 | 8635 | 0.010 |
Why?
|
Sequence Deletion | 1 | 2004 | 1494 | 0.010 |
Why?
|
Selection, Genetic | 1 | 2004 | 870 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2003 | 20555 | 0.010 |
Why?
|
Autopsy | 1 | 2003 | 1006 | 0.010 |
Why?
|
Quality of Life | 1 | 2020 | 13355 | 0.010 |
Why?
|
China | 1 | 2004 | 2348 | 0.010 |
Why?
|
Reference Values | 1 | 2004 | 4921 | 0.010 |
Why?
|
Antibodies, Monoclonal | 1 | 2010 | 9180 | 0.010 |
Why?
|
Liver Diseases | 1 | 2002 | 1296 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2006 | 12450 | 0.010 |
Why?
|
Pilot Projects | 1 | 2002 | 8632 | 0.010 |
Why?
|